117 related articles for article (PubMed ID: 1429919)
1. Development of a stable oral liquid dosage form of spironolactone.
Pramar Y; Das Gupta V; Bethea C
J Clin Pharm Ther; 1992 Aug; 17(4):245-8. PubMed ID: 1429919
[TBL] [Abstract][Full Text] [Related]
2. Development of oral liquid dosage forms of acetazolamide.
Parasrampuria J; Das Gupta V
J Pharm Sci; 1990 Sep; 79(9):835-6. PubMed ID: 2273470
[TBL] [Abstract][Full Text] [Related]
3. Design of freeze-dried Soluplus/polyvinyl alcohol-based film for the oral delivery of an insoluble drug for the pediatric use.
Shamma R; Elkasabgy N
Drug Deliv; 2016; 23(2):489-99. PubMed ID: 24892631
[TBL] [Abstract][Full Text] [Related]
4. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Eckhardt M; Vermes A; Koch BC; Vulto AG; Hanff LM
Eur J Pharm Sci; 2017 Mar; 100():205-210. PubMed ID: 28126558
[TBL] [Abstract][Full Text] [Related]
5. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
Allen LV; Erickson MA
Am J Health Syst Pharm; 1996 Sep; 53(17):2073-8. PubMed ID: 8870895
[TBL] [Abstract][Full Text] [Related]
6. Preformulation studies of spironolactone: effect of pH, two buffer species, ionic strength, and temperature on stability.
Pramar Y; Gupta VD
J Pharm Sci; 1991 Jun; 80(6):551-3. PubMed ID: 1941547
[TBL] [Abstract][Full Text] [Related]
7. Nanoamorphous drug products - Design and development.
Jog R; Burgess DJ
Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
[TBL] [Abstract][Full Text] [Related]
8. Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats.
Sarkar M; Grossman RG; Toups EG; Chow DS
Eur J Pharm Sci; 2018 Dec; 125():1-10. PubMed ID: 30201516
[TBL] [Abstract][Full Text] [Related]
9. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
10. Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt.
Graves R; Phan KV; Bostanian LA; Mandal TK; Pramar YV
Int J Pharm Compd; 2017; 21(4):334-338. PubMed ID: 28719376
[TBL] [Abstract][Full Text] [Related]
11. Flexible New Dosage Forms Containing Carvedilol for the Treatment of Patients with Cardiovascular Disorders: Development, Stability, Palatability, and Microbiological Studies.
Operto MA; Maggio R; Leonardi D; Vignaduzzo S
AAPS PharmSciTech; 2023 Jul; 24(6):159. PubMed ID: 37498506
[TBL] [Abstract][Full Text] [Related]
12. Development of a safe and versatile suspension vehicle for pediatric use: Formulation development.
Alarie H; Roullin VG; Leclair G
Int J Pharm; 2019 Oct; 569():118552. PubMed ID: 31376465
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles.
Elkordy AA; Tan XN; Essa EA
Eur J Pharm Biopharm; 2013 Feb; 83(2):203-23. PubMed ID: 22960707
[TBL] [Abstract][Full Text] [Related]
14. Effect of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer on bioadhesion and release rate property of eplerenone pellets.
Kendre PN; Chaudhari PD
Drug Dev Ind Pharm; 2017 May; 43(5):751-761. PubMed ID: 27494543
[TBL] [Abstract][Full Text] [Related]
15. Effect of pH, chlorobutanol, cysteine hydrochloride, ethylenediaminetetraacetic acid, propylene glycol, sodium metabisulfite, and sodium sulfite on furosemide stability in aqueous solutions.
Shah KA; Das Gupta V; Stewart KR
J Pharm Sci; 1980 May; 69(5):594-6. PubMed ID: 6770073
[TBL] [Abstract][Full Text] [Related]
16. Novel Alternating Current Electrospinning of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) Nanofibers for Dissolution Enhancement: The Importance of Solution Conductivity.
Balogh A; Farkas B; Pálvölgyi Á; Domokos A; Démuth B; Marosi G; Nagy ZK
J Pharm Sci; 2017 Jun; 106(6):1634-1643. PubMed ID: 28257818
[TBL] [Abstract][Full Text] [Related]
17. Stability of refrigerated miglustat after preparation in InOrpha(®) flavored suspending excipient for compounding of oral solutions and suspensions.
Riahi S; Ambühl M; Stichler J; Bandilla D
Drug Des Devel Ther; 2015; 9():561-6. PubMed ID: 25632223
[TBL] [Abstract][Full Text] [Related]
18. Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.
Kim DW; Kim YH; Yousaf AM; Kim DS; Kwon TK; Park JH; Kim YI; Park JH; Jin SG; Kim KS; Cho KH; Li DX; Kim JO; Yong CS; Woo JS; Choi HG
Arch Pharm Res; 2016 Apr; 39(4):539-546. PubMed ID: 26983932
[TBL] [Abstract][Full Text] [Related]
19. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids.
Allen LV; Erickson MA
Am J Health Syst Pharm; 1996 Oct; 53(19):2304-9. PubMed ID: 8893069
[TBL] [Abstract][Full Text] [Related]
20. The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
Jonkman-De Vries JD; Rosing H; Henrar RE; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 1995; 49(6):283-8. PubMed ID: 8581459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
